Your browser doesn't support javascript.
loading
Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment.
Dutta, Sara; Chang, Kelly C; Beattie, Kylie A; Sheng, Jiansong; Tran, Phu N; Wu, Wendy W; Wu, Min; Strauss, David G; Colatsky, Thomas; Li, Zhihua.
Afiliación
  • Dutta S; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
  • Chang KC; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
  • Beattie KA; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
  • Sheng J; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
  • Tran PN; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
  • Wu WW; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
  • Wu M; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
  • Strauss DG; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
  • Colatsky T; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
  • Li Z; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationSilver Spring, MD, United States.
Front Physiol ; 8: 616, 2017.
Article en En | MEDLINE | ID: mdl-28878692
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Physiol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Physiol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos